术后早期注射A型肉毒毒素预防内眦成形术后增生性瘢痕:分脸双盲随机试验
该分脸双盲随机试验纳入43例Park Z内眦成形术患者,术后第6-7天在内眦区注射5 U A型肉毒毒素或等量生理盐水,30例完成随访。肉毒毒素侧温哥华瘢痕量表评分显著改善,3个月时最明显,视觉模拟量表评分在1、3、6个月均显著降低,约86.7%患者对瘢痕和手术效果满意,无严重并发症。
要点
- 内眦成形术后第6-7天注射5 U A型肉毒毒素可显著改善温哥华瘢痕量表评分。
- 改善在术后3个月最明显,瘢痕高度和柔韧性改善最显著。
- 视觉模拟量表评分在1、3、6个月随访均显著降低,约86.7%患者满意。
核心结论
- 术后早期内眦区注射A型肉毒毒素能有效减少增生性瘢痕并改善内眦成形术效果。
- A型肉毒毒素注射可作为预防增生性瘢痕和改善内眦成形术效果的常规方法。
研究设计与样本
- 分脸、双盲、随机对照试验,43例连续同意接受Park Z内眦成形术的患者随机分配。
- 术后第6-7天在内眦区注射5 U A型肉毒毒素或等量生理盐水,30例完成试验。
- 采用温哥华瘢痕量表、视觉模拟量表和患者满意度在1、3、6个月随访独立评估。
主要发现
- A型肉毒毒素治疗侧温哥华瘢痕量表评分显著改善,3个月随访时改善最明显。
- 温哥华瘢痕量表四个子评分中,瘢痕高度和柔韧性改善最显著。
- A型肉毒毒素治疗侧视觉模拟量表评分在1、3、6个月随访均显著降低。
- 约86.7%患者对瘢痕和内眦成形术效果满意,无严重并发症报告。
临床怎么用
- 内眦成形术后第6-7天可考虑在内眦区注射5 U A型肉毒毒素以预防增生性瘢痕。
- 注射后应使用温哥华瘢痕量表和视觉模拟量表在1、3、6个月随访评估瘢痕。
局限性
- 43例随机患者中仅30例完成试验,存在失访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postoperative hypertrophic scarring of the medial canthal area is a common phenomenon and deterrent for patients considering epicanthoplasty. Botulinum toxin type A has been reported for hypertrophic scar and keloid treatment. However, there is a lack of high-level evidence regarding the effects of botulinum toxin type A in the medial canthal area. METHODS: In this split-face, double-blind, randomized trial, 43 consecutive consenting patients undergoing Park Z-epicanthoplasty were randomized to receive 5 U of botulinum toxin type A or the same volume of saline injections at days 6 to 7 postoperatively. Scars were assessed independently using the Vancouver Scar Scale, the visual analogue scale, and patient satisfaction rating at the 1-, 3-, and 6-month follow-ups. RESULTS: Overall, 30 patients completed this trial. The botulinum toxin type A-treated side achieved significantly improved Vancouver Scar Scale scores. The most obvious improvements were observed at the 3-month follow-up visit. Among the four subscores of the Vancouver Scar Scale, the most significantly improved subscores were the height and pliability. The visual analogue scale scores also decreased significantly on the botulinum toxin type A-treated side at all three follow-up visits. Approximately 86.7 percent of the patients were satisfied with the scar and epicanthoplasty outcomes. No severe complications were reported. CONCLUSIONS: Early postoperative botulinum toxin type A injection in the medial canthal region efficiently reduces hypertrophic scarring and improves the outcome of epicanthoplasty. Therefore, botulinum toxin type A injection can be used as a routine method to prevent hypertrophic scarring and improve the outcome of epicanthoplasty. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, II.
引用
- Huang RL, Ho CK, Tremp M, et al. Early Postoperative Application of Botulinum Toxin Type A Prevents Hypertrophic Scarring after Epicanthoplasty: A Split-Face, Double-Blind, Randomized Trial. Plast Reconstr Surg. 2019. PMID: 31568286. doi:10.1097/PRS.0000000000006069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。